Rabies Immunoglobulin Recall Follows Potency Stability Failure

MHRA says Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin 500 IU solution for injection after a stability failure caused a reduction in potency. The agency says the action is intended to prevent any potential reduction in clinical effectiveness and notes that no adverse event reports had been received related to the defect at the time of the notice.

This is a strong example of how product stability issues can sit right at the intersection of quality, clinical effectiveness, and patient protection. For safety teams, recalls like this reinforce that not every urgent safety matter begins with an adverse reaction.